Trials / Completed
CompletedNCT00890175
Staccato Loxapine Pulmonary Safety in Patients With Asthma
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Alexza Pharmaceuticals, Inc. · Unknown
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled loxapine @ 0 & 10 h | 10 mg, 2 doses, 10 hours apart |
| DRUG | Inhaled placebo @ 2 & 10 hours | placebo, 2 doses, 10 hours apart |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-04-29
- Last updated
- 2017-03-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00890175. Inclusion in this directory is not an endorsement.